N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial.

Support Care CancerOct 4, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)Open access

Motahareh Tahmasebi, Romina Kaveh-Ahangaran, Maryam Barkhordar et al.

✦ AI-curated · Sources linked

In 30 seconds

This double-blind randomized controlled trial evaluated the efficacy of N-acetylcysteine (NAC) mouthwash in preventing oral mucositis (OM) in 106 hematopoietic cell transplant (HCT) recipients. While NAC did not significantly reduce the overall incidence of OM, it significantly decreased the occurrence of severe OM (5.6% vs 25.0%, P = 0.006).

Key findings

  • Any-grade OM occurred in 61.1% of NAC patients compared to 73.1% in the placebo group (P = 0.190).
  • Severe OM was significantly less frequent with NAC (5.6%) than with placebo (25.0%, P = 0.006).
  • The overall distribution of WHO grades favored NAC with a P-value of 0.046.
  • NAC was well tolerated with mild and infrequent gastrointestinal adverse events.

Why it matters

Oral mucositis is a common and serious complication in HCT patients. Reducing the severity of OM can improve patient comfort and potentially enhance recovery, making NAC mouthwash a valuable supportive care option.

Source

PubMed · PMID 42829889Free full text on PubMed Central

Published in Support Care Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.